Logical Thought
Hedge fund manager, long/short equity, growth at reasonable price, value

Pain Therapeutics: Very Substantial Risk-Adjusted Upside Vs. Downside

Pain Therapeutics Inc. (NASDAQ:PTIE) is a drug development company that will collect roughly a 20% U.S. royalty and a 10% foreign royalty on what I estimate to be $1.4 billion/year in sales if Pfizer (NYSE:PFE) obtains FDA approval for PTIE's tamperproof (i.e., unattractive to drug addicts) extended release form of oxycodone called Remoxy. Oxycontin -- Purdue Pharma's version of the drug -- does $2.4 billion in U.S. sales and around $400 million more overseas; I think Pfizer - with its superior marketing muscle - should be able to grab at least 50% of that. [DURECT Corporation (NASDAQ:DRRX) will also collect a royalty -- a considerably smaller one than PTIE's -- from Pfizer on sales...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details